Press Releases

Press Releases

IVI welcomes the First Lady of South Korea to a solidarity event for global health and vaccine equity

LINE and International Vaccine Institute Release BT21 Donation Stickers to Promote Global Vaccination and Vaccine Development

IVI welcomes H.E. Einar H. Jensen, Ambassador of Denmark to South Korea, to discuss COVID-19 and AMR research

IVI partners with Seoul National University Hospital to start Phase 1/2 clinical trial of INOVIO’s COVID-19 DNA (INO-4800) vaccine in South Korea

CEPI awards up to US$14.1million to consortium of IVI and Bharat Biotech to advance development of Chikungunya vaccine in collaboration with Ind-CEPI

IVI standardizes on Veeva Vault QualityDocs to Improve Operational Efficiency

IVI presents COVID-19 vaccine and epidemiology research to H.E. Philippe Lefort, Ambassador of France to Korea

IVI to strengthen COVID-19 surveillance in sub-Saharan Africa with support from Sweden

INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference

LINE and International Vaccine Institute Team Up to Promote the Importance of Vaccination

IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO’s COVID-19 DNA vaccine in South Korea

International Vaccine Institute and Technical University of Denmark to strengthen external quality assurance in the face of rising antimicrobial resistance in Asia

IVI and Sweden renew partnership to accelerate vaccines for global public health

IVI to lead critical standard reagents availability for oral cholera vaccine manufacturing to ensure their uniform efficacy and help meet global demand

IVI appoints three new members to its Board of Trustees

IVI to Accelerate Efforts in iNTS Vaccine Development

IVI acquires GCLP certification from Korean Ministry of Food and Drug Safety

IVI Awarded $4.5 Million Grant to Increase Accessibility of Oral Cholera Vaccine

IVI Discusses Expanding Support for Global Collaboration on Vaccine R&D and Delivery with Top Foreign Diplomats in Seoul

IVI-led Consortium Awarded Fleming Fund Regional Grant to Improve Data Sharing in Fight against Antimicrobial Resistance

IVI to help developing countries tackle the spread of infectious diseases by building capacity through vaccinology training in Seoul

IVI acquires supplemental funding for Severe Typhoid in Africa Program (SETA Plus)

IVI Director General Dr. Jerome Kim to join the Human Vaccines Project’s Efforts as One of Four Distinguished Global Leaders to Decode the Human Immune System

Prof. Young Chul Sung, biotech leader, personally donates US$8.4 million to IVI

New push to develop world’s first vaccine against the deadly Strep A bacteria killing hundreds of thousand

IVI-led CAPTURA consortium wins Fleming Fund award for work on antimicrobial resistance (AMR) data across Asia

IVI receives $15.7 million grant to conduct phase III trials of new Vi-DT typhoid conjugate vaccine manufactured by SK bioscience of Korea

‘IVI Forum for Enhancement of Cooperation’ hosted jointly by the Korean Parliamentary Forum for Global Health, and KCDC under MOHW

Vaccine study confirms sensitivity of cholera test

Korean Pediatric Association, IVI, KSC exchange MOU

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

CEPI partners with IVI to accelerate development of vaccines against emerging global health threats

Henry Lau joins IVI as Goodwill Ambassador

Nature Communications study addresses MDR typhoid

THSTI, IVI held joint symposium on Nov. 22

‘The Euvichol story’ published in Vaccine

IVI accelerates development of MERS vaccine

IVI’s 18th Vaccinology Course gathers 120 international participants from 19 countries in Seoul September 3-7

KOICA, IVI team up with Mozambican MoH and INS, partners to vaccinate 190,000 people against cholera

IVI acquires $5 million grant to support process development, scale up of typhoid conjugate vaccine with SK Bioscience



2018-04-20 02:18


The International Vaccine Institute (IVI), Seoul, Korea invites proposals from interested vendors for the supply of following goods and services.

1. Ref. No: IVI-PRNC/2018-0329-1
2. Time limit to submit the proposals: May 3 (Thu) 2018, 17:00, South Korea local time
3. Goods and services to supply: Redesign and update IVI website in English and host the site on the cloud. Please refer to the Attachment 2, “Technical Specification” for details.
4. Documents to submit:
1) Company profile
2) Proposal consisting of;
a. Price proposal: This should include a English website renewal fee, a monthly webhosting fee, warranty(1year), and maintenance plan
b. Technical proposal: This should include delivery time, company’s strength, personnel allocation plan, technical support plan and maintenance plan etc.
3) Financial and bank credit information of the vendor
4) Experience & reference details on similar jobs for the past 3years
5) URL links that the vendor has developed in recent 3years and is in operation
6) Copy of business registration
* For details, please refer to the “Attachment 1, Bid Guideline”
5. Bid briefing session: April 25 (Wed), 2018, 2:00pm, at IVI, Seoul Korea

IVI will review the proposals and select the bona fide vendor based on their ability, experience and financial terms. IVI reserves the right to cancel the bidding procedure if bids are not qualified. The short-listed bidders will be invited for presentation. A final successful bidder shall be notified to accept and sign the contract at the earliest.

Interested parties, please submit the requested documents to:

Ms. Claire (Heeyoung) Kang
International Vaccine Institute
SNU Research Park, 1 Gwanak-ro, Gwanak-gu,
Seoul, Korea 08826

For any questions, please contact Ms. Claire (Heeyoung) Kang at
Attachment : Bid_Guideline.docx